These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 20401461

  • 1. Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.
    Duan SZ, Usher MG, Foley EL, Milstone DS, Brosius FC, Mortensen RM.
    Diabetologia; 2010 Jul; 53(7):1493-505. PubMed ID: 20401461
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.
    Dallaire P, Bellmann K, Laplante M, Gélinas S, Centeno-Baez C, Penfornis P, Peyot ML, Latour MG, Lamontagne J, Trujillo ME, Scherer PE, Prentki M, Deshaies Y, Marette A.
    Diabetes; 2008 Aug; 57(8):1999-2011. PubMed ID: 18458147
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.
    Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML.
    J Biol Chem; 2003 Sep 05; 278(36):34268-76. PubMed ID: 12805374
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
    Kim HJ, Jung TW, Kang ES, Kim DJ, Ahn CW, Lee KW, Lee HC, Cha BS.
    Metabolism; 2007 May 05; 56(5):676-85. PubMed ID: 17445544
    [Abstract] [Full Text] [Related]

  • 10. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.
    Diabetologia; 2007 Aug 05; 50(8):1723-31. PubMed ID: 17520238
    [Abstract] [Full Text] [Related]

  • 11. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.
    Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T.
    Diabetes; 2005 Dec 05; 54(12):3358-70. PubMed ID: 16306350
    [Abstract] [Full Text] [Related]

  • 12. CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo.
    Ming Y, Hu X, Song Y, Liu Z, Li J, Gao R, Zhang Y, Mei H, Guo T, Xiao L, Wang B, Wu C, Xiao X.
    PLoS One; 2014 Dec 05; 9(7):e102102. PubMed ID: 25004107
    [Abstract] [Full Text] [Related]

  • 13. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.
    Lessard SJ, Rivas DA, Chen ZP, Bonen A, Febbraio MA, Reeder DW, Kemp BE, Yaspelkis BB, Hawley JA.
    Diabetes; 2007 Jul 05; 56(7):1856-64. PubMed ID: 17440174
    [Abstract] [Full Text] [Related]

  • 14. Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment.
    Takasawa K, Kubota N, Terauchi Y, Kadowaki T.
    Endocr J; 2008 Aug 05; 55(4):767-76. PubMed ID: 18506083
    [Abstract] [Full Text] [Related]

  • 15. Role and mechanism of rosiglitazone on the impairment of insulin secretion induced by free fatty acids on isolated rat islets.
    Tian JY, Li G, Gu YY, Zhang HL, Zhou WZ, Wang X, Zhu HD, Luo TH, Luo M.
    Chin Med J (Engl); 2006 Apr 05; 119(7):574-80. PubMed ID: 16620699
    [Abstract] [Full Text] [Related]

  • 16. Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue.
    Stienstra R, Duval C, Keshtkar S, van der Laak J, Kersten S, Müller M.
    J Biol Chem; 2008 Aug 15; 283(33):22620-7. PubMed ID: 18541527
    [Abstract] [Full Text] [Related]

  • 17. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
    Mensink M, Hesselink MK, Russell AP, Schaart G, Sels JP, Schrauwen P.
    Int J Obes (Lond); 2007 Aug 15; 31(8):1302-10. PubMed ID: 17310221
    [Abstract] [Full Text] [Related]

  • 18. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.
    Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti P, Del Prato S.
    Am J Physiol Endocrinol Metab; 2004 Apr 15; 286(4):E560-7. PubMed ID: 14625208
    [Abstract] [Full Text] [Related]

  • 19. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet.
    Matsui J, Terauchi Y, Kubota N, Takamoto I, Eto K, Yamashita T, Komeda K, Yamauchi T, Kamon J, Kita S, Noda M, Kadowaki T.
    Diabetes; 2004 Nov 15; 53(11):2844-54. PubMed ID: 15504964
    [Abstract] [Full Text] [Related]

  • 20. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
    Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H.
    Diabetes; 2004 Aug 15; 53(8):2169-76. PubMed ID: 15277403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.